{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-071702","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.927798+00:00","generated_at":"2026-05-16T00:10:30.128430+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Catalyst reports record FY2025 revenue $589M (+20% YoY); FY2026 guidance $615-645M","bullets":["Full year 2025 total revenues $589.0M, up 19.8% YoY; GAAP diluted EPS $1.68 vs $1.31.","Q4 2025 total revenues $152.6M; FIRDAPSE revenue grew 18.3% in Q4; AGAMREE grew 67.5%.","FY2026 revenue guidance $615M-$645M; promoted product revenue expected to grow 20%+.","Non-GAAP net income $346.2M for FY2025 vs $276.3M, up 25.3%.","Cash and equivalents $709.2M as of Dec 31, 2025, up 37% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-071702","json":"https://secwatch.observer/filing/0001193125-26-071702.json","markdown":"https://secwatch.observer/filing/0001193125-26-071702.md","text":"https://secwatch.observer/filing/0001193125-26-071702.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526071702/0001193125-26-071702-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526071702/d108222d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:10:30.128430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}